Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 760-766

  McQuaid, Fiona ^a   Snape, Matthew D ^a   John, Tessa M ^a   Kelly, Sarah ^a   Robinson, Hannah ^a   Houlden, Jennifer ^a   Voysey, Merryn ^a   Toneatto, Daniela ^b   Kitte, Claudia ^a,b   Dull, Peter M ^c   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

persistence; reactogenicity; Serogroup B meningococcus; vaccine

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; BLOOD; FEMALE; IMMUNOLOGY; INFANT; MALE; SERUM BACTERICIDAL ACTIVITY; TIME;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; TIME FACTORS;

EID: 84902536488     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000327     Document Type: Article

References (35)

1. Novartis Bexsero summary of product characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002333/WC500137881.pdf, Accessed November 1, 2013
2. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-e79.
3. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-1137.
4. Vesikari T, Esposito S, Prymula R, et al.; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825-835.
5. Gossger N, Snape MD, Yu LM, et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-582.
6. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013;32:1116-1121.
7. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-5107.
8. Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines. 2013;12:837-858.
9. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child. 2011;96:744-751.
10. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-737.
11. Pollard AJ, Green C, Sadarangani M, et al. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Arch Dis Child. 2013;98:248-251.
12. Ishola DA Jr, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19:1126-1130.
13. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416-425.
14. Department of Health. JCVI Interim position statement on use of Bexsero meningococcal B vaccine in the UK. July 24, 2013. Available at: https://www.gov.uk/government/publications/jcvi-interim-position-statement- onthe- use-of-bexsero-meningococcal-b-vaccine-in-the-uk. Accessed July 29, 2013.
15. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary- school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50:1601-1610.
16. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24:128-131.
17. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694-1698.
18. Department of Health. Chapter 22: Meningococcal. Immunisation against infectious diseases: the Green Book. Updated May 2013. Available at: https://www.gov.uk/government/publications/meningococcal-the-greenbook-chapter- 22. Accessed September 2013.
19. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
20. Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638-2646.
21. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112-B116.
22. Gorringe AR, Paján R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8:174-183.
23. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30:3710-3716.
24. Bettinger JA, Scheifele DW, Halperin SA, et al.; members of the Canadian Immunization Monitoring Program, Active (IMPACT). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine. 2013;32:124-130.
25. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968-4974.
26. Snape MD, Medini D, Halperin SA, et al. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine. 2012;30(suppl 2):B67-B72.
27. Health Protection Agency. Invasive Meningococcal B infections laboratory reports England and Wales by age group and epidemiological year 1998/99-2011/12. Updated September 12, 2012. Available at: http://www.hpa.org.uk. Accessed April 29, 2013.
28. Santolaya ME, O'Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9.
29. Read R, Baxter D, Chadwick D, et al. Impact of a quadrivalent conjugate (MenACWY CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. Meningitis Research Foundation Conference; 2013.
30. Ferrera G, Cuccia M, Mereu G, et al. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measlesmumps- rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Hum Vaccin Immunother. 2012;8:355-362.
31. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007;26:153-158.
32. Santolaya ME, O'Ryan ML, Valenzuela MT, et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebocontrolled study. Lancet. 2012;379:617-624.
33. Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483-486.
34. Nøkleby H, Aavitsland P, O'Hallahan J, et al. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25:3080-3084.
35. Hoiseth SK, Murphy E, Andrew L, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J. 2013;32:1096-1101.